Conexeu Sciences (CNXU) Registration filing summary

Company overview and business model

• Early-stage medical device company developing a patented, temperature-responsive collagen-based ECM scaffold (CXU™) for regenerative tissue applications in wound care, aesthetics, dentistry, veterinary medicine, and 3D bioprinting.

• Incorporated in 2022, acquired core IP from the University of British Columbia, and domesticated into Nevada in 2025.

• CXU™ transitions from liquid to gel in situ, supporting tissue integration and healing; preclinical studies show promising results, but no FDA clearance yet.

• Platform approach targets multiple large, growing markets with a single device backbone, leveraging patent protection in the US, EU, Japan, and Australia.

• Business model focuses on staged regulatory and commercial entry, starting with wound care and expanding to other indications as approvals are obtained.

Financial performance and metrics

• No revenues to date; net loss of $3.92M for the year ended October 31, 2025, up from $0.47M in 2024, reflecting increased R&D, management, and regulatory expenses.

• Cash and cash equivalents of $4.81M as of October 31, 2025, with an additional $2M received in November 2025.

• Raised over $9M in fiscal 2025 through private placements and a $5M Regulation Crowdfunding offering.

• Accumulated deficit of $4.52M as of October 31, 2025; substantial doubt exists about ability to continue as a going concern without further financing.

• Total assets of $7.69M and shareholders’ equity of $7.35M as of October 31, 2025.

Use of proceeds and capital allocation

• No proceeds from resale of registered shares; proceeds up to $1.67M may be received from warrant exercises.

• Capital raised is allocated to regulatory submissions, manufacturing scale-up, pilot programs, and ongoing R&D.

• Near-term capital needs include $1.62M for FDA 510(k) submission, $250K for manufacturing scale-up, and $225K for market entry and pilot programs through fiscal 2027.